Death for Dynavax’s Lead Drug Candidate
Dynavax Technologies Corp. (NASDAQ: DVAX) is feeling the wrath of the markets after an FDA panel said that there was insufficient data to support its investigational Hepatitis B drug called ...Read Full Story »
